<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="54576">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02395653</url>
  </required_header>
  <id_info>
    <org_study_id>PD2013-002</org_study_id>
    <nct_id>NCT02395653</nct_id>
  </id_info>
  <brief_title>Safety and Clinical Utility Study of SSEC Fentanyl 40 mcg for Acute Post-op Pain Management in Pediatric Patients</brief_title>
  <official_title>An Open Label Evaluation of the Safety and Clinical Utility of the Active, Separated System With Enhanced Controller (SSEC) Fentanyl 40mcg for the Management of Acute Postoperative Pain in Pediatric Patients 12 to Less Than 18 Years of Age</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The Medicines Company</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>The Medicines Company</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this study is to evaluate the safety and clinical utility of the active,
      SSEC fentanyl 40 mcg for the management of acute, postoperative pain in pediatric patients.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      An open label evaluation of the safety and clinical utility of the active, separated system
      with enhanced controller (SSEC) fentanyl 40 mcg for the management of acute postoperative
      pain in pediatric patients 12 to less than 18 years of age.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2015</start_date>
  <completion_date type="Actual">September 2016</completion_date>
  <primary_completion_date type="Actual">September 2016</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>Open Label</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Assess Safety</measure>
    <time_frame>0 hour - 7 days following end of study drug administration</time_frame>
    <description>Adverse events (AEs) will be recorded in accordance with ICH definitions. AEs and application site reactions (ASRs) monitored. AEs monitored from the time of application of the first system through 7 days following end of study drug administration.</description>
  </primary_outcome>
  <other_outcome>
    <measure>Skin Irritation Score</measure>
    <time_frame>1 hour - 24 hours following the removal of each Study System</time_frame>
    <description>Skin irritation at the SSEC application site assessed prior to placement of the Study System and at 1 and 24 hours after removal of each Study System.</description>
  </other_outcome>
  <other_outcome>
    <measure>Patient's Ability to Use SSEC</measure>
    <time_frame>At 72 hour or at the time of patient's termination of study treatment</time_frame>
    <description>4-level categorical evaluation to assess the patient's ability to use the SSEC safely and effectively at the time of termination.</description>
  </other_outcome>
  <other_outcome>
    <measure>Adherence of the SSEC</measure>
    <time_frame>Immediately prior to removal - at each 24-hour time point</time_frame>
    <description>The adhesion of each SSEC evaluated immediately prior to removal at each 24-hour time point, or at early withdrawal.</description>
  </other_outcome>
  <other_outcome>
    <measure>Serum Fentanyl Concentration</measure>
    <time_frame>0 hour - 24 hours</time_frame>
    <description>Serum concentrations versus time data will be analyzed using non-compartmental analysis.</description>
  </other_outcome>
  <other_outcome>
    <measure>Vital Signs</measure>
    <time_frame>0 hour - 72 hours</time_frame>
    <description>Vital signs will be measured at baseline (hour 0), 30 minutes, hours 1, 2, 3, 4, 6, 8, 10 and 12 after first system application and every 4 hours thereafter until 72 hours or early withdrawal</description>
  </other_outcome>
  <other_outcome>
    <measure>Numeric Rating Scale (NRS)</measure>
    <time_frame>30 minutes after the patient is awake and comfortable - 72 hours</time_frame>
    <description>Pain intensity ratings measured using the 11-point NRS. Measurements will begin 30 minutes after the patient is awake and comfortable, at the time time of the first system assembly and application (Hour 0), and subsequently at Hours 0.5, 1, 2, 3, 4, 6, 8, 10, and 12 after SSEC application and at 4-hour intervals, up to a maximum of 72 hours.</description>
  </other_outcome>
  <other_outcome>
    <measure>Global Assessments</measure>
    <time_frame>Every 24 hours - 72 hours</time_frame>
    <description>Global assessments of the SSEC as a method of pain control will be obtained at each 24-hour time point, and at early withdrawal.</description>
  </other_outcome>
  <other_outcome>
    <measure>Opioid Rescue Medication</measure>
    <time_frame>0 hour - 72 hours</time_frame>
    <description>Opioid rescue medication number of SSEC doses delivered, and duration of fentanyl exposure.</description>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">62</enrollment>
  <condition>Pain, Postoperative</condition>
  <arm_group>
    <arm_group_label>SSEC Fentanyl</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Separated System with Enhanced Controller (SSEC) fentanyl iontophoretic transdermal system, 40 mcg fentanyl per activation</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fentanyl</intervention_name>
    <description>An opioid that has been administered parenterally as an anesthetic and analgesic for more than 20 years.</description>
    <arm_group_label>SSEC Fentanyl</arm_group_label>
    <other_name>IONSYS</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients whose parent(s) or guardian(s) have/has signed and dated an informed consent
             form for the patient to participate in the study, or patients who have provided
             written assent to participate in the study

          -  Male or female inpatients, age 12 to &lt; 18 years of age inclusive on the day of
             surgery

          -  Patients capable of understanding and cooperating with the requirements of the study,
             including being able to report their pain intensity using the 11-point NRS and
             operate the SSEC

          -  American Society of Anesthesiologists (ASA) physical status I, II or III

          -  Body weight of at least 40.0 kg

          -  Postoperative patients who have undergone general or regional anaesthesia for
             abdominal, pelvic/genitourinary, orthopaedic, or thoracic surgery

          -  Postoperative patients who have been observed during recovery and are expected to
             remain hospitalized and have pain requiring parenteral opioids (i.e., IV PCA) for the
             next 24 hours or longer

          -  Patients who are awake and breathing spontaneously with a respiratory rate of 14 to
             18 breaths per minute, SpO2 ≥ 93% (with or without supplemental oxygen), and able to
             answer questions and follow commands

          -  Patients who have been observed during recovery, who are awake, able to answer
             questions and follow commands, and who have been comfortable for at least 30 minutes,
             with a pain intensity score ≤ 4 (numeric rating scale 0 - 10), with or without
             titration to comfort with IV opioids

        Exclusion Criteria:

          -  Patients who have undergone any surgery on the airway, head, or neck

          -  Patients who received an extended-release opioid within 48 hours prior to Hour 0 or
             who are expected to have postoperative analgesia supplied by a continuous regional
             technique or patient-controlled epidural analgesia

          -  Patients with a history of allergy or hypersensitivity to fentanyl, skin adhesives,
             and/or cetylpyridinium chloride

          -  Patients who are expected to require intensive care or will likely require additional
             surgical procedures within 36 hours

          -  Patients who received intra-operative and/or postoperative administration of opioids
             other than morphine, hydromorphone, fentanyl, sufentanil, or alfentanil. Exception:
             If there are no medical contraindications, meperidine (pethidine) up to 0.5 mg/kg IV
             is permitted during recovery for shivering

          -  Patients who require airway support (nasal or oropharyngeal airway intubation, or
             laryngeal mask airway [LMA]) at the time of final baseline assessments (i.e., at the
             time of IONSYS application [Hour 0])

          -  Patients who are known or suspected to be opioid tolerant, have a history of opioid
             dependence within 3 months before the start of the study, or who are known to hav
             eused illicit drugs or alcohol within 14 days of the start of the study

          -  Patients with active generalized skin disorders or active local skin disease that
             precludes SSEC application to the chest or upper arm

          -  Patients with any coexisting major medical conditions that are likely to interfere
             with study procedures including, but not limited to, psychiatric conditions, chronic
             depression, suicidal ideation, autism

          -  Positive pregnancy test for any female
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>18 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Elliot J Krane, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Stanford Children's Health</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Packard Children's Hospital at Stanford</name>
      <address>
        <city>Palo Alto</city>
        <state>California</state>
        <zip>94304</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Miami/Jackson Memorial Hospital</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Healthcare of Atlanta</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30342</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Johns Hopkins Hospital, Charlotte R. Bloomberg Children's Center</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21287</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Louis Children's Hospital</name>
      <address>
        <city>St. Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Children's Hospital of Philadelphia</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Hospital of Pittsburgh of UPMC</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15224</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Medical Center of Dallas</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75235</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Harborview Medical Center</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Hospital of Wisconsin</name>
      <address>
        <city>Milwaukee</city>
        <state>Wisconsin</state>
        <zip>53226</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Chelly JE, Grass J, Houseman TW, Minkowitz H, Pue A. The safety and efficacy of a fentanyl patient-controlled transdermal system for acute postoperative analgesia: a multicenter, placebo-controlled trial. Anesth Analg. 2004 Feb;98(2):427-33, table of contents.</citation>
    <PMID>14742382</PMID>
  </reference>
  <reference>
    <citation>Grond S, Hall J, Spacek A, Hoppenbrouwers M, Richarz U, Bonnet F. Iontophoretic transdermal system using fentanyl compared with patient-controlled intravenous analgesia using morphine for postoperative pain management. Br J Anaesth. 2007 Jun;98(6):806-15. Erratum in: Br J Anaesth. 2008 Jan;100(1):146.</citation>
    <PMID>17519263</PMID>
  </reference>
  <reference>
    <citation>Hartrick CT, Bourne MH, Gargiulo K, Damaraju CV, Vallow S, Hewitt DJ. Fentanyl iontophoretic transdermal system for acute-pain management after orthopedic surgery: a comparative study with morphine intravenous patient-controlled analgesia. Reg Anesth Pain Med. 2006 Nov-Dec;31(6):546-54.</citation>
    <PMID>17138198</PMID>
  </reference>
  <reference>
    <citation>Minkowitz HS, Rathmell JP, Vallow S, Gargiulo K, Damaraju CV, Hewitt DJ. Efficacy and safety of the fentanyl iontophoretic transdermal system (ITS) and intravenous patient-controlled analgesia (IV PCA) with morphine for pain management following abdominal or pelvic surgery. Pain Med. 2007 Nov-Dec;8(8):657-68.</citation>
    <PMID>18028044</PMID>
  </reference>
  <reference>
    <citation>Minkowitz HS, Yarmush J, Donnell MT, Tonner PH, Damaraju CV, Skowronski RJ. Safety and tolerability of fentanyl iontophoretic transdermal system: findings from a pooled data analysis of four clinical trials. J Opioid Manag. 2010 May-Jun;6(3):203-10.</citation>
    <PMID>20642249</PMID>
  </reference>
  <reference>
    <citation>Viscusi ER, Reynolds L, Chung F, Atkinson LE, Khanna S. Patient-controlled transdermal fentanyl hydrochloride vs intravenous morphine pump for postoperative pain: a randomized controlled trial. JAMA. 2004 Mar 17;291(11):1333-41.</citation>
    <PMID>15026400</PMID>
  </reference>
  <reference>
    <citation>Viscusi ER, Reynolds L, Tait S, Melson T, Atkinson LE. An iontophoretic fentanyl patient-activated analgesic delivery system for postoperative pain: a double-blind, placebo-controlled trial. Anesth Analg. 2006 Jan;102(1):188-94.</citation>
    <PMID>16368828</PMID>
  </reference>
  <reference>
    <citation>Viscusi ER, Siccardi M, Damaraju CV, Hewitt DJ, Kershaw P. The safety and efficacy of fentanyl iontophoretic transdermal system compared with morphine intravenous patient-controlled analgesia for postoperative pain management: an analysis of pooled data from three randomized, active-controlled clinical studies. Anesth Analg. 2007 Nov;105(5):1428-36, table of contents.</citation>
    <PMID>17959978</PMID>
  </reference>
  <verification_date>September 2016</verification_date>
  <lastchanged_date>September 15, 2016</lastchanged_date>
  <firstreceived_date>March 10, 2015</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Pediatric</keyword>
  <keyword>Postoperative</keyword>
  <keyword>Pain Management</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Pain, Postoperative</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Fentanyl</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
